Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame
Primary	Number of participants with treatment-related adverse events as assesses by CTCAE version 4.03.	58 weeks
Primary	Determine the recommended phase 2 dose (RP2D) based on Dose limiting toxicities	6 weeks
Secondary	To evaluate the investigator assessed ORR using standard response evaluation criteria in solid tumors (RECIST) version 1.1 for metastatic renal cell carcinoma.	2 years
Secondary	To evaluate the investigator assessed ORR using standard response evaluation criteria in solid tumors (RECIST) version 1.1 for metastatic urothelial cancer.	2 years
Secondary	To evaluate median progression free survival (PFS) using Kaplan-Meier curves for metastatic renal cell carcinoma.	2 years
Secondary	To evaluate median progression free survival (PFS) using Kaplan-Meier curves for metastatic urothelial cancer.	2 years
Secondary	To evaluate median overall survival (OS) using Kaplan-Meier curves for metastatic renal cell carcinoma.	2 years
Secondary	To evaluate median overall survival (OS) using Kaplan-Meier curves for metastatic urothelial cancer.	2 years
Secondary	To investigate the relationship between PD-L1 expression on tumor cells and on immune cells using IHC and SMI methods.	Baseline
Secondary	To investigate the relationship between PD-L1 expression on tumor cells and on immune cells using IHC and SMI methods.	week 2
Secondary	To investigate the relationship between PD-L1 expression on tumor cells and on immune cells using IHC and SMI methods.	week 7

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02614456/registered